Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
BridgeBio announced the publication of post-hoc analyses in Circulation: Heart Failure showing that acoramidis (Attruby) provides direct kidney-protective effects in ATTR-CM patients. The data revealed a 15.5% reduction in UACR by Day 28 and a sustained improved chronic eGFR slope through Month 30, alongside a 58% lower risk of death or cardiovascular hospitalization in the first year.
Key figures
- Egfr slope
- +2.47 mL/min/1.73m²/year
- Uacr reduction day 28
- 15.5%
- Uacr reduction month 30
- 13.7%
- Hr hospitalization alone
- 0.34
- Adverse event diarrhea attruby
- 11.6%
- Adverse event diarrhea placebo
- 7.6%
- Hr death or cv hospitalization
- 0.42
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.